JP2006520397A - 新規融合トリアゾロン類及びその使用 - Google Patents

新規融合トリアゾロン類及びその使用 Download PDF

Info

Publication number
JP2006520397A
JP2006520397A JP2006507956A JP2006507956A JP2006520397A JP 2006520397 A JP2006520397 A JP 2006520397A JP 2006507956 A JP2006507956 A JP 2006507956A JP 2006507956 A JP2006507956 A JP 2006507956A JP 2006520397 A JP2006520397 A JP 2006520397A
Authority
JP
Japan
Prior art keywords
triazolo
methyl
quinolin
phenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520397A5 (enExample
Inventor
アッシュウェル，スーザン
エズサチャン，ジャヤチャンドラン
ライン，ポール・ダーモット
ニューコーム，ニコラス・ジョン
パス，マーティン
オザ，ヴィバ
スー，メイ
トーダー，ドリン
ユー，ディンウェイ
ユー，ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2006520397A publication Critical patent/JP2006520397A/ja
Publication of JP2006520397A5 publication Critical patent/JP2006520397A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2006507956A 2003-03-14 2004-03-10 新規融合トリアゾロン類及びその使用 Pending JP2006520397A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45507303P 2003-03-14 2003-03-14
US46769003P 2003-05-02 2003-05-02
US53634304P 2004-01-14 2004-01-14
PCT/SE2004/000351 WO2004081008A1 (en) 2003-03-14 2004-03-10 Novel fused triazolones and the uses thereof

Publications (2)

Publication Number Publication Date
JP2006520397A true JP2006520397A (ja) 2006-09-07
JP2006520397A5 JP2006520397A5 (enExample) 2007-05-10

Family

ID=32995996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507956A Pending JP2006520397A (ja) 2003-03-14 2004-03-10 新規融合トリアゾロン類及びその使用

Country Status (10)

Country Link
US (1) US20070149560A1 (enExample)
EP (1) EP1613625A1 (enExample)
JP (1) JP2006520397A (enExample)
KR (1) KR20050119647A (enExample)
AU (1) AU2004220176A1 (enExample)
BR (1) BRPI0408256A (enExample)
CA (1) CA2519107A1 (enExample)
MX (1) MXPA05009885A (enExample)
NO (1) NO20054083L (enExample)
WO (1) WO2004081008A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150123005A (ko) * 2014-04-24 2015-11-03 동아에스티 주식회사 아졸계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
JPWO2005063222A1 (ja) 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
AU2006214247C1 (en) 2005-02-16 2012-11-08 Anacor Pharmaceuticals, Llc Boron-containing small molecules
NZ556718A (en) * 2005-02-18 2010-10-29 Astrazeneca Ab Method for determining responsiveness to CHKI inhibitors
KR20080074963A (ko) * 2005-11-10 2008-08-13 쉐링 코포레이션 단백질 키나제 억제제로서의 이미다조피라진
BRPI0621279B1 (pt) 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
CN102532180B (zh) * 2005-12-30 2016-06-29 安纳考尔医药公司 含硼的小分子
EP1978966A4 (en) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US8012965B2 (en) 2006-12-29 2011-09-06 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2009002955A1 (en) * 2007-06-27 2008-12-31 Sanofi-Aventis U.S. Llc Process for the preparation of (2r)-2-[4-(7-bromo-2-quinolyloxy)phenoxy]propanoic acid
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
WO2010004319A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt
CA2749843C (en) 2009-01-16 2017-09-05 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US8614221B2 (en) 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
JP2013518886A (ja) 2010-02-03 2013-05-23 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼ阻害剤
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN104884449A (zh) 2012-10-31 2015-09-02 拜尔农作物科学股份公司 作为害虫防治剂的新的杂环化合物
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
TW202342477A (zh) 2022-03-01 2023-11-01 香港商英矽智能科技知識產權有限公司 二醯基甘油激酶(DGK) α抑制劑及其用途
WO2023165528A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
CN120225518A (zh) * 2022-11-15 2025-06-27 伊莱利利公司 Ahr激动剂
CN119874716B (zh) * 2025-03-27 2025-07-15 上海隆盛化工有限公司 1-氯-6,8-二氟-7-异丙基苯并呋喃并[2,3-c]吡啶及其合成方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953457A (en) * 1972-07-28 1976-04-27 Eli Lilly And Company Agent for the control of plant-pathogenic organisms
JPS5697286A (en) * 1979-09-24 1981-08-05 Bristol Myers Co Triazoloquinolones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953457A (en) * 1972-07-28 1976-04-27 Eli Lilly And Company Agent for the control of plant-pathogenic organisms
JPS5697286A (en) * 1979-09-24 1981-08-05 Bristol Myers Co Triazoloquinolones

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150123005A (ko) * 2014-04-24 2015-11-03 동아에스티 주식회사 아졸계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
KR102164612B1 (ko) 2014-04-24 2020-10-12 동아에스티 주식회사 아졸계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제

Also Published As

Publication number Publication date
US20070149560A1 (en) 2007-06-28
BRPI0408256A (pt) 2006-03-01
NO20054083D0 (no) 2005-09-02
NO20054083L (no) 2005-10-10
EP1613625A1 (en) 2006-01-11
CA2519107A1 (en) 2004-09-23
MXPA05009885A (es) 2005-12-05
KR20050119647A (ko) 2005-12-21
AU2004220176A1 (en) 2004-09-23
WO2004081008A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
JP2006520397A (ja) 新規融合トリアゾロン類及びその使用
US12171739B2 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
AU2019246753B2 (en) Novel compounds and compositions for inhibition of FASN
CN101119968B (zh) 作为甘氨酸转运蛋白1抑制剂的杂环取代的苯基甲酮衍生物
JP5516397B2 (ja) オーロラキナーゼ調節物質及び使用方法
CN105102453B (zh) 作为布罗莫结构域抑制剂的苯并咪唑酮衍生物
TWI527800B (zh) 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
CA2564085C (en) Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
ES2649144T3 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
TWI576346B (zh) 雙環吡嗪酮衍生物
CN116723843A (zh) 用于治疗和/或预防癌症的sos1抑制剂的药物组合
WO2019037678A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN103534254A (zh) 作为抗肿瘤剂的三环和四环吡唑并[3,4-b]吡啶化合物
JP2008534664A (ja) 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
JP2007517843A (ja) Ｃｈｋ１阻害剤であるチオフェン誘導体
PL211125B1 (pl) Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
JP2010533674A (ja) Ｍｋ２阻害剤として有用なヘテロ環式化合物
CN103261156A (zh) 用于治疗神经退化性疾病的新化合物
JPH0784460B2 (ja) ヒドロキシキノロン誘導体
JPH06145170A (ja) ヘテロ環式化合物、その製法及びこれを含有する高血圧及びうつ血性心不全治療用医薬組成物
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
WO2024249817A1 (en) Tricyclic pkmyt1 kinase inhibitors
CN100482663C (zh) 新型稠合三唑酮及其用途
CN101268072A (zh) Dna-pk抑制剂
HK40018685A (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110104